Clinical Development
Clinical strategy, trial design, protocol development, and regulatory interface for Phase I through Phase III programs.
Key Capabilities
- Phase I first-in-human study design and dose escalation strategy
- Phase II proof-of-concept trial design
- Phase III pivotal trial strategy and protocol development
- Clinical pharmacology and PK/PD strategy
- Biomarker and endpoint strategy
- FDA meeting preparation and regulatory interactions
- Clinical operations oversight and CRO management
Our Approach
Bionavigen brings deep clinical development expertise to help clients design and execute efficient, high-quality clinical programs. Our team has experience across oncology, immunology, and rare diseases.
We provide strategic guidance on all aspects of clinical development, from first-in-human dose selection through pivotal trial design. Our experience with FDA interactions and BLA/NDA submissions ensures that clinical programs are designed to meet regulatory requirements.
Our consultants work as an extension of your team, providing hands-on support for protocol development, regulatory submissions, and clinical operations to accelerate your program timeline.